p53 Expression in Reed-Sternberg cells does not correlate with gene mutations in Hodskin's disease

American Journal of Clinical Pathology

Volumn 106, Issue 6, 1996, Pages 728-738

  Elenitoba Johnson, Kojo S J ^a,b   Medeiros, L Jeffrey ^a,c   Khorsand, Jila ^a   King, Thomas C ^a,d  

^a BROWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d MIRIAM HOSPITAL   (United States)

Author keywords

Hodgkin's disease; mdm 2; Mutation; p53; SSCP

Indexed keywords

PROTEIN P53;

ARTICLE; CORRELATION FUNCTION; GENE MUTATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, VIRAL; CHILD; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; GENES, IMMUNOGLOBULIN; GENES, P53; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REED-STERNBERG CELLS; TUMOR SUPPRESSOR PROTEIN P53; VIRAL MATRIX PROTEINS;

EID: 0030448036     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.6.728     Document Type: Article

References (52)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-456.
3. Martinez J, Georgoff I, Levine AJ. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 1991;5:151-159.
4. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342: 705-708.
5. Caron de Fromentel C, Soussi T. p53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chrom Cancer 1992;4:1-15.
6. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799.
7. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984;312:646-649.
8. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-679.
9. Wynford-Thomas D. p53 in tumor pathology: Can we trust immunohistochemistry? J Pathol 1992;166:329-330.
10. Pasman PC, Tiesbosch A, Erdkamp FL, Vrints LW, Breed WP, Schouten HC. p53 as a marker of the malignant cell in Hodgkin's disease. Ann Oncol 1994;5(suppl 7):89-91.
11. Chilosi M, Montagna L, Lestani M, Menestrina F, Mariuzzi GM. Quantitative approach to the immunohistochemical analysis of p53 antioncogene and CD30 antigen in Hodgkin's disease. In Vivo 1993;7:393-394.
12. Hubbert NL Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinoocytes. J Virol 1992;66:6237-6241.
13. Luka J, Jornvall H, Klein G. Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit. J Virol 1980;35:592-602.
14. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987;129:86-91.
15. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternbergcells. Proc Natl Acad Sci USA 1991;88:4766-4770.
16. Herbst H, Niedobitek G, Kneba M, et al. High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol 1990;137:13-18.
17. Deacon EM, Pallesen G, Niedobitek G, Brooks L, Rickinson AB, Young LS. Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993; 177: 339-349.
18. Moorthy RK, Thorley-Lawson D. Biochemical, genetic, and functional analyses of the phosphorylation sites on the EBV-encoded oncogenic latent membrane protein LMP-1. J Virol 1993;67: 2637-2645.
19. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
20. Chilosi M, Doglioni C, Menestrina F, et al. Abnormal expression of the p53-binding protein mdm-2 in Hodgkin's disease. Blood 1994;84:4295-4300.
21. Vidal-Puig A, Moller DE. Comparative sensitivity of alternative single-strand conformation polymorphism (SSCP) methods. BioTechniques 1994;17:490-496.
22. Gown AM, de Wever N, Battifora H. Microwave-based antigenic unmasking. A revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 1993;1:256-266.
23. Forsthoefel KF, Papp AC, Snyder PJ, Prior TW. Optimization of DNA extraction from formalin fixed tissue and its clinical application in Duchenne muscular dystrophy. Am J Clin Pathol 1992;98:98-104.
24. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Postthymic T-cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 1994;144:573-584.
25. Orita M, Suzuki Y, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the p7olymerase chain reaction. Genomics 1989;5:874-879.
26. Elenitoba-Johnson, K, Medeiros, LJ, Khorsand, J, King TC. Lymphoma of the mucosa-associated lymphoid tissue of the lung: A multifocal case of common clonal origin. Am J Clin Pathol 1995;103:341-345.
27. McCarthy KP, Sloane JP, Kabarowsi JHS, Matutes E, Wiedmann LM. A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene. Diagn Mol Pathol 1992;1:173-179.
28. Chittal SM, Caveriviere P, Schwarting R, et al. Monoclonal antibodies in the diagnosis of Hodgkin's disease: The search for a rational panel. Am J Surg Pathol 1988;12:9-21.
29. Kamel OW, Chang PP, Grank BS, et al. Clonal VDJ recombination of the immunoglobulin heavy chain gene by PCR in classical Hodgkin's disease. Am J Clin Pathol 1995;104:419-423.
30. Orazi A, Jiang B, Lee C-H, et al. Correlation between presence of clonal rearrangements of immunoglobulin heavy chain gene and B-cell antigen expression in Hodgkin's disease. Am J Clin Pathol 1995;104:413-418.
31. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein coding region of the human p53 gene. Gene 1988;70:245-252.
32. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M. Immunohistochemical evidence for abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol Pathol 1991;5: 67-73.
33. Niedobitek G, Rowlands DC, Young LS, et al. Overexpression of p53 in Hodgkin's disease: Lack of correlation with Epstein-Barr virus infection. J Pathol 1993;169:207-212.
34. Xerri L, Pare P, Bouabdallah R, Camerlo J, Hassoun J. PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease. J Pathol 1995;175:189-194.
35. Inghirami G, Macri L, Rosati S, Zhu BY, Yee HT, Knowles DM. The Reed-Stern berg cells of Hodgkin disease are clonal. Proc Natl Acad Sci USA 1994;91:9842-9846.
36. Trumper LH, Brady G, Bagg A, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: Molecular Heterogeneity of gene expression and p53 mutations. Blood 1993;81:3097-3115.
37. Gupta RK, Patel K, Bodmer WF, Bodmer JG. Mutation of p53 in primary biopsy material and cell lines from Hodgkin's disease. Proc Natl Acad Sci USA 1993;90:2817-2821.
38. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature 1992;357:82-84.
39. Grand RJ, Lecane PS, Owen D, et al. The high levels of p53 present in adenovirus early region 1-transformed human cells do not caouse up-regulation of MDM2 expression. Virology 1995;210: 323-334.
40. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40 transformed cells. Nature 1979;278:261-263.
41. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein mdm-2. Nature 1995;375:694-698.
42. Maestro R, Gloghini A, Boglioni C, et al. MDM2 overexpression does not account for stablization of wild-type p53 in non-Hodgkin's lymphomas. Blood 1995;85:3239-3246.
43. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinog 1995;12:124-131.
44. Zhou M, Yearer AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995;85:1608-1614.
45. Barbareschi M, Girlando S, Fellin G, Graffer U, Luciani L, Dalla Palma P. Expression of mdm-2 and p53 protein in transitonal cell carcinoma. Urol Res 1995;22:349-352.
46. McCann AH, Kirley A, Carney DN, et al. Amplificaton of the MDM2 gene in human breast cancer and its associaton with MDM2 and p53 protein status. Br J Cancer 1995;71:981-985.
47. Gerdes J, Van Baarlen J, Pileri S, Schwarting R, Van Unnik JAM, Stein H. Tumor cell growth fraction in Hodgkin's disease. Am J Pathol 1987;129:390-393.
48. Pecham MJ, Cooper EH. Proliferation characteristics of varying classes of cell in Hodgkin's disease. Cancer 1969;24:135-139.
49. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-7495.
50. Fritsche M, Haessler C, Brandner G. Production of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-318.
51. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992;89:9210-9214.
52. Hummel M, Ziemann K, Lammert H, Piler S, Sabattini E, Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternbergcells. N Engl J Med 1995;333:901-906.